|
시장보고서
상품코드
1859939
세계의 암 유전자 치료 : 시장 점유율과 순위, 전체 판매 및 수요 예측(2025-2031년)Gene Therapies for Cancer Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031 |
||||||
QYResearch
암 유전자 치료 시장 규모는 2024년에 82억 3,000만 달러로 평가되었고, 2025-2031년의 예측 기간에 CAGR 18.5%로 성장하여 2031년까지 304억 900만 달러에 이를 것으로 예측됩니다.
암 유전자 치료는 환자의 유전체를 직접 변형시켜 암을 치료하는 혁신적인 치료법입니다. 주요 전략으로는 키메라 항원 수용체 T세포(CAR-T) 치료, CRISPR-Cas9 등 유전자 편집 기술, 바이러스 벡터를 통한 유전자 도입 등이 있습니다. 기존의 화학요법이나 방사선 치료와 비교하여 유전자 치료는 분자 수준에서 암 유전자를 복구 또는 대체하거나, 면역체계를 활성화시켜 종양세포를 인식하고 제거하거나, 항종양 면역반응을 강화함으로써 보다 높은 특이성과 맞춤 치료의 이점을 제공합니다. 암 유전자 치료는 혈액 악성 종양(백혈병, 림프종 등)과 고형 종양(폐암, 유방암 등)을 포함한 다양한 암종에 적용할 수 있습니다. 높은 비용, 제조의 복잡성, 장기적 유효성 등의 과제가 남아있지만, 임상시험에서 입증된 효과로 인해 유전자 치료는 종양학에서 중요한 연구방향으로 자리매김하고 있습니다.
암 유전자 치료 시장은 몇 가지 주요 요인으로 인해 빠르게 진화하고 있습니다. 첫째, 암 발생률 증가와 기존 치료법의 한계로 인해 새로운 치료 옵션에 대한 수요가 증가하고 있습니다. 둘째, 유전자 편집 기술과 세포공학 기술의 발전으로 암 유전자 치료제의 개발 및 제조가 더욱 실현 가능해졌습니다. 셋째, 맞춤형 의료 및 정밀의료에 대한 규제당국의 지원정책이 유전자치료의 임상적용에 유리한 환경을 조성하고 있습니다. 넷째, 환자의 치료 효과와 삶의 질에 대한 관심이 높아지면서 혁신적인 치료법에 대한 수요가 증가하고 있습니다. 또한, 바이오제약기업과 연구기관과의 협력이 기술이전 및 제품개발을 가속화하고 있습니다.
암 유전자 치료는 큰 잠재력을 가지고 있지만, 몇 가지 과제와 위험이 여전히 남아있습니다. 첫째, 개별화된 세포 처리와 유전자 편집을 수반하는 고가의 치료비용이 환자와 의료시스템의 부담을 가중시키고 있습니다. 둘째, 세포 채취, 유전자 변형, 증식, 재투여를 포함한 제조 공정이 복잡하고, 그 어떤 편차도 유효성과 안전성에 영향을 미칠 수 있습니다. 셋째, 장기적인 효과와 잠재적인 부작용에 대해서는 아직 완전히 밝혀지지 않았으며, 검증을 위해서는 더 많은 임상 데이터가 필요합니다. 넷째, 규제 당국의 승인 절차가 복잡하고 시간이 오래 걸리기 때문에 새로운 치료법 시장 출시가 지연될 수 있습니다. 다섯째, 시장은 경쟁이 치열하고 수많은 기업과 연구기관이 연구개발에 투자하고 있어 기술 및 제품의 동질화 위험이 높아지고 있습니다.
암 유전자 치료에 대한 다운스트림 수요는 다음과 같은 추세를 보이고 있습니다. 첫째, 정밀의료의 개념이 널리 보급되면서 환자와 의료기관의 개인 맞춤형 치료 계획에 대한 수요가 증가하고 있습니다. 둘째, 유효성 데이터가 축적되면서 특히 난치성 및 재발암 환자를 중심으로 유전자 치료를 고려하는 환자가 증가하고 있습니다. 셋째, 보험사 및 지불 기관이 유전자 치료의 적용 범위를 점차 확대하면서 환자의 경제적 부담이 줄어들고 있습니다. 넷째, 치료의 안전성과 삶의 질에 대한 환자들의 우려로 인해 부작용 억제와 치료 요법의 최적화에 초점을 맞춘 연구개발이 진행되고 있습니다. 또한, 환자 교육 및 정보 접근성 향상으로 새로운 치료법에 대한 수용성이 높아지고 있습니다.
이 보고서는 암 치료용 유전자 치료 세계 시장에 대해 총 매출액, 주요 기업의 시장 점유율 및 순위에 초점을 맞추고 지역/국가, 유형 및 용도별 분석을 종합적으로 제시하는 것을 목적으로 합니다.
암 치료용 유전자 치료 시장 규모 추정 및 예측은 매출액 기준으로 제시되며, 2024년을 기준 연도로 하여 2020년부터 2031년까지의 과거 데이터와 예측 데이터를 포함합니다. 정량적, 정성적 분석을 통해 독자들이 암 치료용 유전자 치료제 관련 사업 전략 및 성장 전략 수립, 시장 경쟁 평가, 현재 시장에서의 자사 위치 분석, 정보에 입각한 사업적 판단을 내릴 수 있도록 지원합니다.
시장 세분화
목차
기업별
- Biogen
- Novartis
- Gilead Sciences
- Sarepta Therapeutics
- Sunway Biotech
- SIBIONO
- AnGes
- Orchard Therapeutics
- Human Stem Cells Institute
유형별 부문
- 바이러스 벡터
- 비바이러스 벡터
용도별 부문
- 고형 종양
- 혈액 악성 종양
지역별
- 북미
- 미국
- 캐나다
- 아시아태평양
- 중국
- 일본
- 한국
- 동남아시아
- 인도
- 호주
- 기타 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 네덜란드
- 북유럽 국가
- 기타 유럽
- 라틴아메리카
- 멕시코
- 브라질
- 기타 라틴아메리카
- 중동 및 아프리카
- 튀르키예
- 사우디아라비아
- 아랍에미리트(UAE)
- 기타 중동 및 아프리카
The global market for Gene Therapies for Cancer Treatment was estimated to be worth US$ 8230 million in 2024 and is forecast to a readjusted size of US$ 30409 million by 2031 with a CAGR of 18.5% during the forecast period 2025-2031.
Cancer gene therapy is an innovative treatment approach that involves directly modifying the patient's genome to treat cancer. Common strategies include Chimeric Antigen Receptor T-cell (CAR-T) therapy, gene editing technologies such as CRISPR-Cas9, and viral vector-mediated gene transduction. Compared to traditional chemotherapy and radiotherapy, gene therapies offer higher specificity and personalized advantages by repairing or replacing oncogenes at the molecular level, activating the immune system to recognize and eliminate tumor cells, or enhancing anti-tumor immune responses. Cancer gene therapies are applicable to various cancer types, including hematologic malignancies (such as leukemia and lymphoma) and solid tumors (such as lung and breast cancer). Although challenges remain, such as high costs, manufacturing complexities, and long-term efficacy, the demonstrated effectiveness in clinical trials positions gene therapy as a significant research direction in oncology.
The cancer gene therapy market is rapidly evolving, driven by several key factors: First, the rising incidence of cancer and the limitations of traditional treatments have increased the demand for novel therapeutic options. Second, advancements in gene editing and cell engineering technologies have made the development and production of cancer gene therapies more feasible. Third, supportive policies from regulatory agencies regarding personalized and precision medicine have created a favorable environment for the clinical application of gene therapies. Fourth, patients' focus on efficacy and quality of life has driven the demand for innovative treatments. Additionally, collaborations between biopharmaceutical companies and research institutions have accelerated the translation of technologies and product development.
Despite the significant potential of cancer gene therapies, several challenges and risks persist. First, the high treatment costs, involving personalized cell processing and gene editing, increase the burden on patients and healthcare systems. Second, the manufacturing process is complex, encompassing cell collection, gene modification, expansion, and reinfusion, with any deviation potentially impacting efficacy and safety. Third, the long-term efficacy and potential side effects are not yet fully understood, requiring more clinical data for validation. Fourth, the regulatory approval processes are cumbersome and time-consuming, potentially delaying the market introduction of new therapies. Fifth, the market is highly competitive, with numerous companies and research institutions investing in R&D, leading to increased risks of technological and product homogeneity.
Downstream demand for cancer gene therapies is exhibiting the following trends: First, with the widespread adoption of precision medicine concepts, there is an increasing demand from patients and healthcare institutions for personalized treatment plans. Second, as efficacy data accumulates, more cancer patients, especially those with refractory or relapsed conditions, are considering gene therapies. Third, insurance companies and payers are gradually expanding coverage for gene therapies, reducing the financial burden on patients. Fourth, patients' concerns about treatment safety and quality of life are prompting research and development to focus more on controlling side effects and optimizing treatment regimens. Additionally, improvements in patient education and information access have enhanced acceptance of new therapies.
This report aims to provide a comprehensive presentation of the global market for Gene Therapies for Cancer Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Gene Therapies for Cancer Treatment by region & country, by Type, and by Application.
The Gene Therapies for Cancer Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapies for Cancer Treatment.
Market Segmentation
By Company
- Biogen
- Novartis
- Gilead Sciences
- Sarepta Therapeutics
- Sunway Biotech
- SIBIONO
- AnGes
- Orchard Therapeutics
- Human Stem Cells Institute
Segment by Type
- Viral Vectors
- Non-viral Vectors
Segment by Application
- Solid Tumors
- Hematologic Malignancies
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Gene Therapies for Cancer Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Gene Therapies for Cancer Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Gene Therapies for Cancer Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 Gene Therapies for Cancer Treatment Product Introduction
- 1.2 Global Gene Therapies for Cancer Treatment Market Size Forecast (2020-2031)
- 1.3 Gene Therapies for Cancer Treatment Market Trends & Drivers
- 1.3.1 Gene Therapies for Cancer Treatment Industry Trends
- 1.3.2 Gene Therapies for Cancer Treatment Market Drivers & Opportunity
- 1.3.3 Gene Therapies for Cancer Treatment Market Challenges
- 1.3.4 Gene Therapies for Cancer Treatment Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global Gene Therapies for Cancer Treatment Players Revenue Ranking (2024)
- 2.2 Global Gene Therapies for Cancer Treatment Revenue by Company (2020-2025)
- 2.3 Key Companies Gene Therapies for Cancer Treatment Manufacturing Base Distribution and Headquarters
- 2.4 Key Companies Gene Therapies for Cancer Treatment Product Offered
- 2.5 Key Companies Time to Begin Mass Production of Gene Therapies for Cancer Treatment
- 2.6 Gene Therapies for Cancer Treatment Market Competitive Analysis
- 2.6.1 Gene Therapies for Cancer Treatment Market Concentration Rate (2020-2025)
- 2.6.2 Global 5 and 10 Largest Companies by Gene Therapies for Cancer Treatment Revenue in 2024
- 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapies for Cancer Treatment as of 2024)
- 2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
- 3.1 Introduction by Type
- 3.1.1 Viral Vectors
- 3.1.2 Non-viral Vectors
- 3.2 Global Gene Therapies for Cancer Treatment Sales Value by Type
- 3.2.1 Global Gene Therapies for Cancer Treatment Sales Value by Type (2020 VS 2024 VS 2031)
- 3.2.2 Global Gene Therapies for Cancer Treatment Sales Value, by Type (2020-2031)
- 3.2.3 Global Gene Therapies for Cancer Treatment Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
- 4.1 Introduction by Application
- 4.1.1 Solid Tumors
- 4.1.2 Hematologic Malignancies
- 4.2 Global Gene Therapies for Cancer Treatment Sales Value by Application
- 4.2.1 Global Gene Therapies for Cancer Treatment Sales Value by Application (2020 VS 2024 VS 2031)
- 4.2.2 Global Gene Therapies for Cancer Treatment Sales Value, by Application (2020-2031)
- 4.2.3 Global Gene Therapies for Cancer Treatment Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
- 5.1 Global Gene Therapies for Cancer Treatment Sales Value by Region
- 5.1.1 Global Gene Therapies for Cancer Treatment Sales Value by Region: 2020 VS 2024 VS 2031
- 5.1.2 Global Gene Therapies for Cancer Treatment Sales Value by Region (2020-2025)
- 5.1.3 Global Gene Therapies for Cancer Treatment Sales Value by Region (2026-2031)
- 5.1.4 Global Gene Therapies for Cancer Treatment Sales Value by Region (%), (2020-2031)
- 5.2 North America
- 5.2.1 North America Gene Therapies for Cancer Treatment Sales Value, 2020-2031
- 5.2.2 North America Gene Therapies for Cancer Treatment Sales Value by Country (%), 2024 VS 2031
- 5.3 Europe
- 5.3.1 Europe Gene Therapies for Cancer Treatment Sales Value, 2020-2031
- 5.3.2 Europe Gene Therapies for Cancer Treatment Sales Value by Country (%), 2024 VS 2031
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific Gene Therapies for Cancer Treatment Sales Value, 2020-2031
- 5.4.2 Asia Pacific Gene Therapies for Cancer Treatment Sales Value by Region (%), 2024 VS 2031
- 5.5 South America
- 5.5.1 South America Gene Therapies for Cancer Treatment Sales Value, 2020-2031
- 5.5.2 South America Gene Therapies for Cancer Treatment Sales Value by Country (%), 2024 VS 2031
- 5.6 Middle East & Africa
- 5.6.1 Middle East & Africa Gene Therapies for Cancer Treatment Sales Value, 2020-2031
- 5.6.2 Middle East & Africa Gene Therapies for Cancer Treatment Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions Gene Therapies for Cancer Treatment Sales Value Growth Trends, 2020 VS 2024 VS 2031
- 6.2 Key Countries/Regions Gene Therapies for Cancer Treatment Sales Value, 2020-2031
- 6.3 United States
- 6.3.1 United States Gene Therapies for Cancer Treatment Sales Value, 2020-2031
- 6.3.2 United States Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
- 6.3.3 United States Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Gene Therapies for Cancer Treatment Sales Value, 2020-2031
- 6.4.2 Europe Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
- 6.4.3 Europe Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
- 6.5 China
- 6.5.1 China Gene Therapies for Cancer Treatment Sales Value, 2020-2031
- 6.5.2 China Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
- 6.5.3 China Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
- 6.6 Japan
- 6.6.1 Japan Gene Therapies for Cancer Treatment Sales Value, 2020-2031
- 6.6.2 Japan Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
- 6.6.3 Japan Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
- 6.7 South Korea
- 6.7.1 South Korea Gene Therapies for Cancer Treatment Sales Value, 2020-2031
- 6.7.2 South Korea Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
- 6.7.3 South Korea Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
- 6.8 Southeast Asia
- 6.8.1 Southeast Asia Gene Therapies for Cancer Treatment Sales Value, 2020-2031
- 6.8.2 Southeast Asia Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
- 6.8.3 Southeast Asia Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
- 6.9 India
- 6.9.1 India Gene Therapies for Cancer Treatment Sales Value, 2020-2031
- 6.9.2 India Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
- 6.9.3 India Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
7 Company Profiles
- 7.1 Biogen
- 7.1.1 Biogen Profile
- 7.1.2 Biogen Main Business
- 7.1.3 Biogen Gene Therapies for Cancer Treatment Products, Services and Solutions
- 7.1.4 Biogen Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
- 7.1.5 Biogen Recent Developments
- 7.2 Novartis
- 7.2.1 Novartis Profile
- 7.2.2 Novartis Main Business
- 7.2.3 Novartis Gene Therapies for Cancer Treatment Products, Services and Solutions
- 7.2.4 Novartis Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
- 7.2.5 Novartis Recent Developments
- 7.3 Gilead Sciences
- 7.3.1 Gilead Sciences Profile
- 7.3.2 Gilead Sciences Main Business
- 7.3.3 Gilead Sciences Gene Therapies for Cancer Treatment Products, Services and Solutions
- 7.3.4 Gilead Sciences Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
- 7.3.5 Gilead Sciences Recent Developments
- 7.4 Sarepta Therapeutics
- 7.4.1 Sarepta Therapeutics Profile
- 7.4.2 Sarepta Therapeutics Main Business
- 7.4.3 Sarepta Therapeutics Gene Therapies for Cancer Treatment Products, Services and Solutions
- 7.4.4 Sarepta Therapeutics Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
- 7.4.5 Sarepta Therapeutics Recent Developments
- 7.5 Sunway Biotech
- 7.5.1 Sunway Biotech Profile
- 7.5.2 Sunway Biotech Main Business
- 7.5.3 Sunway Biotech Gene Therapies for Cancer Treatment Products, Services and Solutions
- 7.5.4 Sunway Biotech Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
- 7.5.5 Sunway Biotech Recent Developments
- 7.6 SIBIONO
- 7.6.1 SIBIONO Profile
- 7.6.2 SIBIONO Main Business
- 7.6.3 SIBIONO Gene Therapies for Cancer Treatment Products, Services and Solutions
- 7.6.4 SIBIONO Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
- 7.6.5 SIBIONO Recent Developments
- 7.7 AnGes
- 7.7.1 AnGes Profile
- 7.7.2 AnGes Main Business
- 7.7.3 AnGes Gene Therapies for Cancer Treatment Products, Services and Solutions
- 7.7.4 AnGes Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
- 7.7.5 AnGes Recent Developments
- 7.8 Orchard Therapeutics
- 7.8.1 Orchard Therapeutics Profile
- 7.8.2 Orchard Therapeutics Main Business
- 7.8.3 Orchard Therapeutics Gene Therapies for Cancer Treatment Products, Services and Solutions
- 7.8.4 Orchard Therapeutics Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
- 7.8.5 Orchard Therapeutics Recent Developments
- 7.9 Human Stem Cells Institute
- 7.9.1 Human Stem Cells Institute Profile
- 7.9.2 Human Stem Cells Institute Main Business
- 7.9.3 Human Stem Cells Institute Gene Therapies for Cancer Treatment Products, Services and Solutions
- 7.9.4 Human Stem Cells Institute Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
- 7.9.5 Human Stem Cells Institute Recent Developments
8 Industry Chain Analysis
- 8.1 Gene Therapies for Cancer Treatment Industrial Chain
- 8.2 Gene Therapies for Cancer Treatment Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis (Customers Analysis)
- 8.5 Sales Model and Sales Channels
- 8.5.1 Gene Therapies for Cancer Treatment Sales Model
- 8.5.2 Sales Channel
- 8.5.3 Gene Therapies for Cancer Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
- 10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
- 10.1.1 Methodology/Research Approach
- 10.2 Author Details
- 10.3 Disclaimer
